Denileukin diftitox

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Recombinant fusion protein from interleukin-2 and the diphtheria toxin fragments A and B.

Pharmacodynamics (Effect)This section has been translated automatically.

Denileukin Diftitox interacts with the highly affine forms of the IL-2 receptor (CD25-, CD122-, CD132 pos.) on lymphoma cells in CTCL, activated T- and B-lymphocytes as well as macrophages and thereby inhibits the cellular protein synthesis of these cells (cell death within a few hours).

IndicationThis section has been translated automatically.

Persistent or recurrent cutaneous T-cell lymphomas expressing CD 25.

Pregnancy/nursing periodThis section has been translated automatically.

Contraindicated in pregnancy and lactation (insufficient data available).

Dosage and method of useThis section has been translated automatically.

Therapy cycle with 9-18 mg/kg bw/day (in NaCl 0.9%) i.v. on 5 consecutive days. Before therapy, apply systemic antihistamines, e.g. Dimetinden (Fenistil). Repeat every 21 days.

Remember! Let infusion slowly, for at least 15-30 minutes! Only use infusion containers made of plastic (danger of loss of active substance due to sticking to the container wall in glass containers)!

Undesirable effectsThis section has been translated automatically.

Frequent fever, chills, hypotonia, dehydration, nausea, vomiting, hypoalbuminaemia, anaemia, dyspnoea

InteractionsThis section has been translated automatically.

Not known (insufficient data available)

PreparationsThis section has been translated automatically.

Ontak (not approved in Germany; available from international pharmacies)

Note(s)This section has been translated automatically.

Remember! Response rate according to phase III studies: 38% for CTCL (16% complete remission, 22% partial remission)!

LiteratureThis section has been translated automatically.

  1. Carretero-Margolis CD, Fivenson DP (2003) A complete and durable response to denileukin diftitox in a patient with mycosis fungoides. J Am Acad Dermatol 48: 275-276
  2. Frankel AE et al (2003) A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 9: 3555-3561
  3. Paschal BR (2003) Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy. Leuk lymphoma 44: 731-733
  4. Prince HM et al (2003) Management of the primary cutaneous lymphomas. Australas J Dermatol 44: 227-240
  5. Smith BD, Wilson LD (2003) Management of mycosis fungoides: Part 2. treatment. Oncology 17: 1419-1428

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer